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Abstract
Introduction Overexpression of cyclooxygenase (COX-2) is
commonly observed in human cancers. In a murine model of
metastatic breast cancer, we observed that COX-2 expression
and enzyme activity were associated with enhanced tumorigenic
and metastatic potential. In contrast to the high COX-2
expression in metastatic tumors, transplantation of poorly
tumorigenic tumor cell lines to syngeneic mice results in less
COX-2 expression and less COX-2 activity in vivo. Aberrant
CpG island methylation, and subsequent silencing of the COX-
2 promoter, has been observed in human cancer cell lines and
in some human tumors of the gastrointestinal tract.
Methods Using bisulfite modification and a methylation-specific
PCR, we examined the methylation status of the COX-2
promoter in a series of four closely-related murine mammary
tumors differing in COX-2 expression and metastatic potential.
Results We showed that line 410, which does not express
COX-2  in vivo, exhibited evidence of promoter methylation.
Interestingly, the metastatic counterpart of this cell (line 410.4)
displayed only the unmethylated COX-2 promoter, as did two
additional cell lines (lines 66.1 and 67). The methylation patterns
observed in vitro were maintained when these murine mammary
tumor lines were transplanted to syngeneic mice. Treatment
with the DNA demethylating agent 5-aza-deoxycytidine
increased COX-2 mRNA, increased protein and increased
enzyme activity (prostaglandin synthesis).
Conclusions These results indicate that COX-2  promoter
methylation may be one mechanism by which tumor cells
regulate COX-2 expression. Upregulation of COX-2 expression
in closely related metastatic lesions versus nonmetastatic
lesions may represent a shift towards the unmethylated
phenotype.
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Introduction
It is now well established that the inducible isoform of
cyclooxygenase, COX-2, is commonly overexpressed in
many solid tumors [1,2]. Epidemiological studies as well as
clinical trials employing selective and nonselective COX-2
inhibitors indicate that COX-2 is mechanistically involved in
colorectal carcinogenesis, and possibly in other sites of
carcinogenesis [3-7]. In addition to early cancer develop-
ment, evidence is beginning to accumulate that COX-2
may also contribute to late-stage progression (i.e. tumor
metastasis) [7,8]. Early reports in breast cancer suggested
a linkage between prostaglandin production and aggres-
sive disease [9,10], but less is known regarding the spe-
cific contribution of the COX-2 isoform to behavior. Studies
are beginning to emerge that suggest heightened COX-2
expression is associated with more aggressive breast can-
cer [11-13].
We have examined COX-2 expression in a murine model of
metastatic breast cancer and have observed that COX-2
protein expression in vivo, as well as COX-2 enzyme activ-
ity (i.e. prostaglandin E2 [PGE2] synthesis), is positively cor-
related with more aggressive disease [14]. Furthermore,
selective COX-2 or COX-1 inhibitors control metastatic
disease in this model system [15].
COX-2 expression and PGE2 production were very low or
absent in tumors derived from transplantation of
nonmetastatic cell lines to syngeneic mice, but metastatic
tumors expressed high levels of COX-2 protein, mRNA and
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PGE2. COX-2 expression is controlled in normal tissues at
the transcriptional level. In cancer, expression of many
genes is regulated by aberrant promoter methylation [16].
Several recent studies have likewise suggested that meth-
ylation of COX-2 promoter DNA at areas of CpG islands
may result in aberrant COX-2 methylation in human tumors
of colorectal or gastric origin [17-21]. Based on these stud-
ies, we asked whether COX-2 promoter methylation regu-
lates gene expression in mammary epithelial tumors.
Materials and methods
Cell lines
Four murine mammary tumor cell lines (lines 410, 410.4,
66.1 and 67) were maintained in DMEM medium supple-
mented with 10% fetal calf serum (Gemini Bio-Products,
Inc., Calabasas, CA, USA), 2 mM glutamine, penicillin (100
U/ml), streptomycin (100 µg/ml) and 0.1 mM nonessential
amino acids in a 10% CO2 humidified atmosphere.
For determination of COX expression in tumors, (1–3) ×
106 viable cells of each tumor line were injected subcuta-
neously into syngeneic Balb/cByJ female mice (Jackson
Laboratories, Bar Harbor, ME, USA). When tumors
achieved an average diameter of 8 mm, the mice were sac-
rificed by cervical dislocation, the tumors were removed
and portions were prepared for protein analysis or for DNA
studies.
Bisulfite modification and methylation-specific PCR
Genomic DNA was extracted by the DNA Prep Kit
(Promega, Madison, WI, USA) and was bisulfite modified
with the CpGenomic DNA modification kit (Intergen, Pur-
chase, NY, USA). Methylation-specific PCR was performed
using the later described primer pairs in a volume of 50 µl
containing 1 × PCR buffer, 0.2 mM dNTP, 1.5 mM MgCl2,
50 ng bisulfite-modified genomic DNA, 10 pmol each
sense primer and each antisense primer, and 0.4 U Plati-
num Taq DNA polymerase (Gibco BRL, Gaithersburg, MD,
USA).
The PCR conditions were 95°C for 5 min, then 35 cycles
at 95°C for 45 s, at 60°C for 45 s and at 72°C for 45 s, and
a final extension at 72°C for 4 min. Ten microliters of each
PCR product were loaded on a nondenaturing 10% poly-
acrylamide gel, were stained with ethidium bromide and
were directly visualized under UV illumination.
Mouse Cox-2 primer sequences were designed based on
the published promoter sequence [22]: methylated reac-
tion, 5'-TTTGTCGTTGCGGTTTTTGC-3' (sense) and 5'-
AAAACGAACTCCACGTAACG-3' (antisense), 118 bp
product; unmethylated reaction, 5'-AAAGTTTGTTGTTGT-
GGTTTTTGT-3' (sense) and 5'-CTATAAAACAAACTCCA-
CATAACA-3' (antisense), 126 bp product.
For COX mRNA analysis, RNA was extracted from cultured
cells using TRIAZOL reagent (Gibco BRL), was reverse
transcribed and was amplified using COX-2-specific prim-
ers: forward primer, 5'-GTGGAAAAACCTCGTCCAGA-3'
and reverse primer, 5'-TGATGGTGGCTGTTTTGGTA-3'
(256 bp product).
5-aza-2'-deoxycytidine treatment
Cells were plated in complete medium and treated with
concentrations of 5-aza-2'-deoxycytidine (5-aza) treatment
from 0.1 to 1.0 µM (Sigma Chemical Co., St Louis, MO,
USA) for 4 days. The medium and the drug were replaced
every 24 hours. At the end of the treatment period, the
medium was removed and RNA was extracted for RT-PCR
or northern analysis, protein was extracted for western anal-
ysis or conditioned medium was harvested for PGE2
ELISA.
Western blotting
Cell lysates were prepared in M-Per or tumor lysates were
prepared in T-Per (Pierce, Rockford, IL, USA) containing
phenylmethylsulfonyl fluoride as previously described [14].
Lysates were centrifuged and 20 µg protein was denatured
in Laemmli sample buffer and resolved on 10% Tris-HCl
ready gels (BioRad, Hercules, CA, USA), was electropho-
retically transferred to a nitrocellulose membrane (Amer-
sham Pharmacia Biotech, Piscataway, NJ, USA) and was
immunoblotted with Cox-2 antibody (Cayman Chemical,
Ann Arbor, MI, USA) or β-actin antibody (Sigma) followed
by horseradish peroxidase-conjugated second antibodies
(Transduction Laboratories, Lexington, KY, USA). Specific
bands were visualized by Super Signal West Pico chemilu-
minescent substrate (Pierce).
Prostaglandin E ELISA
Determination of PGE2 levels in cell-conditioned medium
was carried out by ELISA kit following the manufacturer's
instructions (Cayman Chemical). Conditioned medium was
harvested and analyzed for PGE2 72 hours after the addi-
tion of 5-aza.
Results
We examined the role of COX-2 in cancer using a murine
model of metastatic breast cancer. We have shown previ-
ously that metastatic potential is positively correlated with
increased expression and activity of the COX-2 enzyme.
Analysis of COX-2 proteins expressed in lysates of tumors
revealed a strikingly different pattern for metastatic tumors
versus nonmetastatic tumors (Fig. 1). COX-2 protein
expression was present in vivo in metastatic populations
(i.e. lines 66.1, 410.4 and 168) but was nearly absent in
tumors derived from the nonmetastatic cell lines 410 and
67. Only after prolonged exposures was a faint COX-2
band visible from lysates obtained from tumor line 410
(data not shown). These data confirm our earlier report inAvailable online http://breast-cancer-research.com/content/6/4/R316
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which immmunohistochemical staining for COX-2 was evi-
dent in tumors derived from line 66.1 or from 410.4 cell
lines, but not tumors derived from line 410 [14].
Although COX-2 expression is frequently upregulated in
cancers of various histologic types, the mechanisms driving
this expression are not completely elucidated. Multiple
mechanisms are responsible for the regulation of gene
expression. DNA methylation is an epigenetic modification
that can play an important role in silencing of other genes
[16]. Recent studies provide evidence of hypermethylation
of CpG islands within the COX-2 promoter in both breast
and colon human cancer cell lines [17-21]. To determine
whether murine breast tumors employ a similar mechanism
of COX-2 gene regulation, we used methylation-specific
PCR to examine the methylation pattern of the COX-2 pro-
moter in murine tumor cell lines. Figure 2a shows that three
of the four cell lines (lines 66.1, 410.4 and 67) expressed
only the unmethylated promoter (126 bp product), whereas
both unmethylated species and methylated species were
amplified from line 410 (126 bp and 118 bp, respectively).
The methylation patterns observed in cultured tumor cells
were examined in vivo. Tumor cells were transplanted to
syngeneic Balb/cByJ female mice and palpable tumors
were excised. DNA was extracted and analyzed by methyl-
ation-sensitive PCR as already described. This analysis
shows that the methylation patterns expressed in cultured
cells were maintained in solid tumors derived from these
cells (Fig. 2b). Line 410 tumors thus exhibited both methyl-
ated and unmethylated species, whereas tumors derived
from line 66.1, line 410.4 or line 67 expressed only the
unmethylated COX-2 promoter. Figure 2c shows COX-2
and β-actin mRNA expression in the same cell lines. Con-
sistent with the observed promoter methylation pattern,
COX-2 levels were reduced in line 410 cells (approximately
50% of levels observed in line 66.1). We were concerned
that the mixed methylation pattern observed in line 410 cul-
tures might be the result of heterogeneous populations of
cells. We therefore recloned line 410 and re-examined the
COX promoter methylation pattern. Each clonal population
retained the mixed methylation pattern (Fig. 2d).
To determine the role of methylation in silencing of COX-2,
the cell line displaying evidence of promoter methylation
(line 410) was treated with the DNA demethylating agent,
5-aza (0.1–1.0 µM). The effect on COX-2 mRNA and pro-
tein levels was then determined. A modest induction (1.2-
fold to 2.6-fold) of COX-2 mRNA by 5-aza was observed in
a dose-dependent manner (Fig. 3a). This increased COX-2
mRNA expression was associated with an increase in Cox-
2 protein as well (Fig. 3b).
PGE2  levels were assayed to determine whether the
observed effects of 5-aza on the induction of COX-2 pro-
Figure 1
Tumors derived from the transplantation of metastatic lines 66.1, 410.4  and 168 or from nonmetastatic lines 410 and 67 were harvested Tumors derived from the transplantation of metastatic lines 66.1, 410.4 
and 168 or from nonmetastatic lines 410 and 67 were harvested. The 
tissue lysates were prepared and were immunoblotted with cyclooxyge-
nase-2 antibody followed by horseradish peroxidase-conjugated sec-
ondary antibodies, and the expression was compared with 72 kDa Cox-
2 protein standard (STD).
Figure 2
Genomic DNA was extracted from murine mammary tumor cell lines,  was bisulfite modified and was PCR amplified using primer pairs spe- cific for the murine methylated (M) (118 bp) product or the murine  unmethylated (U) (126 bp) product Genomic DNA was extracted from murine mammary tumor cell lines, 
was bisulfite modified and was PCR amplified using primer pairs spe-
cific for the murine methylated (M) (118 bp) product or the murine 
unmethylated (U) (126 bp) product. (a) Ten microliters of PCR product 
were loaded per lane of nondenaturing polyacrylamide gel and were 
stained with ethidium bromide. Lines 66.1, 410.4 and 67 express only 
the unmethylated band, whereas line 410 contains both methylated and 
unmethylated cyclooxygenase-2. (b) Genomic DNA was extracted from 
tumors derived from the transplantation of the indicated cell lines to 
syngeneic mice and was analyzed as in (a). The methylation pattern 
observed in cell lines is maintained when cells are transplanted to mice. 
(c) RNA was extracted from mammary tumor cell lines, was reverse 
transcribed and was amplified using primers specific for either murine 
COX-2 or β-actin. The fold increase was determined by densitometry. 
(d) Clonal populations were derived from line 410, and the DNA 
extracted, bisulfite modified and PCR amplified using primers as in (a). 
Each pair of methylated and unmethylated products represents an indi-
vidual clone.Breast Cancer Research    Vol 6 No 4    Ma et al.
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tein and mRNA are reflected in differences in enzyme activ-
ity. Line 410 cells were treated with 5-aza and, 72 hours
later, the conditioned medium was harvested and analyzed
for PGE2 by ELISA. As predicted by the mRNA and protein
results, treatment of line 410 cells with 5-aza in concentra-
tions of 0.1–0.4 µM resulted in a dose-dependent increase
in PGE2 levels (Fig. 4) consistent with the upregulation in
COX-2 protein levels.
Discussion
Overexpression of COX-2 is commonly observed in solid
tumors of diverse histologic types [1,2]. COX-2  is tran-
scriptionally regulated in normal tissues by many factors
including the proinflammatory cytokines tumor necrosis
factor-α and interleukin-1β as well as bacterial endotoxin.
The molecular basis of COX-2 upregulation in cancer has
not been established, but may in part represent the activa-
tion by stromal factors, host growth factors, and so on. Sev-
eral recent reports have indicated that COX-2 promoter
methylation may represent an additional regulator of
expression in some cancer cell lines and tumors [17-19].
Gene silencing can occur through cytosine methylation of
CpG islands. Other cancer-associated genes have been
shown to be regulated by aberrant hypermethylation of 5'
CpG islands in cancer [16].
Toyota and colleagues first proposed promoter methylation
as a mechanism to regulate COX-2 expression in cancer
[17]. They showed that a subset of colorectal cancers and
adenomas reveals evidence of aberrant COX-2 methyla-
tion. Examination of a number of tumor cell lines revealed
complex patterns, with some cell lines exhibiting dense
methylation and other cell lines exhibiting partial methyla-
tion. Detailed methylation mapping implicated a region
upstream of exon I in loss of COX-2 mRNA expression, an
effect that could be reversed by treatment with 5-aza.
Detailed promoter mapping in gastric carcinoma cell lines
revealed that all CpG sites in the region spanning -590 to
+186, with respect to the transcription initiation site, were
completely methylated [18].
We have examined the role of COX-2 in a model of meta-
static breast cancer. Those studies showed a strong corre-
lation for expression and enzymatic activity of COX-2 with
increased tumorigenic and metastatic potential [14,15].
When nonmetastatic cell lines (lines 410 and 67) were
transplanted to syngeneic mice, no COX-2 protein could
be detected by either immunohistochemistry or immunob-
lotting of tumor lysates. This lack of COX-2 protein expres-
sion was also associated with very weak or absent COX-2
mRNA. In contrast, metastatic tumors (lines 66.1, 410.4,
4526 and 168) express COX-2 in vivo and have much
higher levels of extractable PGE2[14].
Based on studies from other laboratories demonstrating
COX-2 promoter methylation as one mechanism by which
COX-2 is regulated in human cancer, we sought evidence
for  COX-2  promoter methylation in murine mammary
tumors. Using bisulfite modification and methylation-spe-
cific PCR, we compared the COX-2 methylation patterns in
a series of four murine mammary tumor cell lines and
tumors derived from these cell lines. We found that three of
four cell lines (lines 66.1, 67 and 410.4) expressed only the
unmethylated promoter, whereas both unmethylated
species and methylated species were amplified in line 410.
Figure 3
Murine line 410 was treated with 5-aza-2'-deoxycytidine (5-aza) at the  concentrations indicated for 72 hours Murine line 410 was treated with 5-aza-2'-deoxycytidine (5-aza) at the 
concentrations indicated for 72 hours. The RNA was extracted, reverse 
transcribed and amplified using primers specific for either murine 
cyclooxygenase-2 or for β-actin. (a) The fold increase was determined 
by densitometry. (b) Lysates were prepared from cells treated as in (a) 
and were immunoblotted using COX-2-specific antibody or β-actin-spe-
cific antibody. Lane six contains a Cox-2 protein standard (STD).
Figure 4
Line 410 cells were treated with various concentrations of 5-aza-2'- deoxycytidine and, 72 hours after culture initiation, conditioned medium  was harvested and analyzed for prostaglandin E2 (PGE2) by ELISA Line 410 cells were treated with various concentrations of 5-aza-2'-
deoxycytidine and, 72 hours after culture initiation, conditioned medium 
was harvested and analyzed for prostaglandin E2 (PGE2) by ELISA.Available online http://breast-cancer-research.com/content/6/4/R316
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Thus, for line 410.4 and line 66.1 cells there is a correlation
between expression and unmethylated status, and for line
410 there is a lack of expression and methylated status.
Line 67 is the exception to this relationship and suggests
that other mechanisms contribute to COX-2 regulation.
These data confirm previous studies by one of our labora-
tories [19] and those of Toyota and colleagues [17] show-
ing complex COX promoter methylation patterns in human
colorectal cancer cell lines, gastric epithelial cancer cell
lines and breast cancer cell lines. The current findings
extend these studies to indicate that COX-2  promoter
methylation may also be an important mechanism in a
rodent model of breast cancer. The methylation pattern
observed in vitro was maintained when murine tumor cell
lines were transplanted to syngeneic mice. Importantly,
treatment of the cell line that exhibits methylated promoter,
with 5-aza, resulted in increased COX-2 mRNA and protein
consistent with a role for methylation in silencing of the
COX-2  gene. This upregulation by demethylation also
resulted in increased enzyme activity as indicated by
increased production of PGE2.
A comparison of methylation patterns in cell lines 410 and
410.4 is of interest because of the common origin of these
cells with very different phenotypes. Tumors resulting from
transplantation of line 410 are thus relatively slow growing
and rarely metastasize. Line 410.4 was derived from a rare
metastatic lesion occurring in a mouse bearing a subcuta-
neous implant of line 410. Like the behavior of these
tumors, the COX-2 promoter methylation patterns are also
distinct. The loss of COX  promoter methylation in line
410.4 versus line 410 may indicate a mechanistic role for
COX-2 expression in tumor progression. The acquisition of
a more aggressive and metastatic phenotype may thus be
related to increased COX-2 expression in line 410.4 cells
relative to line 410 cells. The current studies extend these
findings to indicate that the upregulation of COX-2 we have
observed during breast cancer progression may some-
times result from reduced methylation of the COX-2 pro-
moter.
It has been suggested that the net expression of COX-2 in
colorectal tumors represents a balance between the pres-
sure to silence many genes, including tumor suppressor
genes, by methylation and the pressure to express COX-2
as a mechanism to inhibit apoptosis and otherwise promote
cancer growth [20]. In the case of tumors derived from line
410, little or no COX-2 mRNA or protein is detectable.
Thus, in this relatively benign lesion, the balance is shifted
towards silencing of this gene that, when expressed, is
associated with more aggressive breast cancers. There is
also evidence in human malignancies that COX-2 is some-
times hypermethylated, possibly representing a balance
between methylation of tumor-promoting genes and tumor-
suppressing genes [17-19,21].
A number of genes have been shown to be hypermethyl-
ated in cancer [16]. Many tumor suppressor genes as well
as other cancer-related genes are inactivated by aberrant
methylation of the CpG islands in the promoter region
including Rb, estrogen receptor, androgen receptor, cyclin
kinase inhibitors, the mismatch repair gene hMLH-1, p73,
mts-1, BRCA-1, thrombospondin-1 and TIMP-3. Methyla-
tion in cancer thus often involves loss of function of an oth-
erwise protective gene activity. Such findings are the basis
for clinical studies to evaluate the therapeutic efficacy of
inhibitors of DNA methylation. The current studies suggest
that the COX-2 gene may be unusual in this regard, since
methylation is associated with decreased tumorigenicity at
least in a murine system.
It will be important to examine COX methylation in primary
human breast tumors to determine whether the pattern
observed in cell lines is confirmed. Furthermore, correlating
levels of COX-2 expression with methylation patterns will
be important to establish the role of COX promoter methyl-
ation in gene expression in human disease. Further studies
are clearly indicated to clarify the role of COX-2 methylation
in breast and other malignancies.
Conclusions
It is now accepted that COX-2 expression plays a role in
the behavior of breast cancer and other malignancies. Less
is known regarding how COX-2 is regulated in cancer, but
the current study adds to the growing body of evidence
that promoter methylation may be involved. Comparison of
closely related metastatic and nonmetastatic counterparts
suggests that the COX-2 promoter may be demethylated
during tumor progression.
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